Embolic protection device, the next advancement in TAVR?
David Li
Nicole Shirakawa
Hong Liu
1.Department of Anesthesiology and Pain Medicine, University of California Davis Health, Sacramento, CA, USA2.Department of Anesthesiology and Pain Medicine, University of California Davis Health, Sacramento, CA, USA3.Department of Anesthesiology and Pain Medicine, University of California Davis Health, Sacramento, CA, USA
摘要：The approval of commercial application transcatheter aortic valve replacement (TAVR) by the FDA in 2011 has revolutionized the management of high-risk surgical patients with severe aortic stenosis (AS).With TAVR being expanded to intermediate surgical risk patients in 2016,the number of patients undergoing TAVR has been increasing rapidly.In fact,since the very first human TAVR procedure in 2002,more than 300,000 TAVRs have been performed worldwide,[1,2] The technological advancements in the TAVR since its early days of clinical adaptation has made this procedure a routine practice in many institutions worldwide.However,one of the most feared complications,ischemic stroke,remains a major concern for clinicians and patients despite all the advancements in the procedure.
机标关键词：
论文发表日期：2020-03-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：4( 160-163 )
英文信息